The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

被引:884
作者
Moasser, M. M. [1 ]
机构
[1] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Med, San Francisco, CA 94143 USA
关键词
HER2; HER-2; ErbB2; ErbB-2; Neu; HER2/Neu;
D O I
10.1038/sj.onc.1210477
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The year 2007 marks exactly two decades since Human Epidermal Growth Factor Receptor-2 (HER2) was functionally implicated in the pathogenesis of human breast cancer. This finding established the HER2 oncogene hypothesis for the development of some human cancers. The subsequent two decades have brought about an explosion of information about the biology of HER2 and the HER family. An abundance of experimental evidence now solidly supports the HER2 oncogene hypothesis and etiologically links amplification of the HER2 gene locus with human cancer pathogenesis. The molecular mechanisms underlying HER2 tumorigenesis appear to be complex and a unified mechanistic model of HER2-induced transformation has not emerged. Numerous hypotheses implicating diverse transforming pathways have been proposed and are individually supported by experimental models and HER2 may indeed induce cell transformation through multiple mechanisms. Here I review the evidence supporting the oncogenic function of HER2, the mechanisms that are felt to mediate its oncogenic functions, and the evidence that links the experimental evidence with human cancer pathogenesis.
引用
收藏
页码:6469 / 6487
页数:19
相关论文
共 227 条
[31]  
CHAZIN VR, 1992, ONCOGENE, V7, P1859
[32]   Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J].
Cho, HS ;
Mason, K ;
Ramyar, KX ;
Stanley, AM ;
Gabelli, SB ;
Denney, DW ;
Leahy, DJ .
NATURE, 2003, 421 (6924) :756-760
[33]   Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines [J].
Choudhury, A ;
Charo, J ;
Parapuram, SK ;
Hunt, RC ;
Hunt, DM ;
Seliger, B ;
Kiessling, R .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (01) :71-77
[34]   ERBB-2 ANTISENSE OLIGONUCLEOTIDES INHIBIT THE PROLIFERATION OF BREAST-CARCINOMA CELLS WITH ERBB-2 ONCOGENE AMPLIFICATION [J].
COLOMER, R ;
LUPU, R ;
BACUS, SS ;
GELMANN, EP .
BRITISH JOURNAL OF CANCER, 1994, 70 (05) :819-825
[35]  
Cool M, 1999, CANCER RES, V59, P2438
[36]   A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution [J].
Crowe, Joseph P. ;
Patrick, Rebecca J. ;
Rybicki, Lisa A. ;
Escobar, Pedro F. ;
Weng, David ;
Budd, G. Thomas ;
Tubbs, Raymond R. ;
Procop, Gary W. ;
Hicks, David G. .
BREAST, 2006, 15 (06) :728-735
[37]   THE SUBCELLULAR-LOCALIZATION OF THE NEU PROTEIN IN HUMAN NORMAL AND NEOPLASTIC-CELLS [J].
DEPOTTER, CR ;
QUATACKER, J ;
MAERTENS, G ;
VANDAELE, S ;
PAUWELS, C ;
VERHOFSTEDE, C ;
EECHAUTE, W ;
ROELS, H .
INTERNATIONAL JOURNAL OF CANCER, 1989, 44 (06) :969-974
[38]  
Deshane J, 1996, CANCER GENE THER, V3, P89
[39]   ERBB-2 IS A POTENT ONCOGENE WHEN OVEREXPRESSED IN NIH/3T3 CELLS [J].
DIFIORE, PP ;
PIERCE, JH ;
KRAUS, MH ;
SEGATTO, O ;
KING, CR ;
AARONSON, SA .
SCIENCE, 1987, 237 (4811) :178-182
[40]   Constitutive MEK/MAPK activation leads to p27Kip1 deregulation and antiestrogen resistance in human breast cancer cells [J].
Donovan, JCH ;
Milic, A ;
Slingerland, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (44) :40888-40895